Cargando…
Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice
BACKGROUND: Regorafenib was previously shown to reduce tumor-associated macrophages and potently inhibit colony-stimulating factor 1 receptor (CSF1R), also known as CD115, in biochemical assays. The CSF1R signaling pathway is essential in the biology of the mononuclear/phagocyte system, which can pr...
Autores principales: | Grünewald, Sylvia, Stecklum, Maria, Rizzo, Manuel, Rathjens, Jonathan, Fiebig, Lukas, Zopf, Dieter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069031/ https://www.ncbi.nlm.nih.gov/pubmed/37013652 http://dx.doi.org/10.1186/s40001-023-01099-2 |
Ejemplares similares
-
Correction: Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice
por: Grünewald, Sylvia, et al.
Publicado: (2023) -
Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017) -
Trafficking of Mononuclear Phagocytes in Healthy Arteries and Atherosclerosis
por: Tomas, Lukas, et al.
Publicado: (2021) -
Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer
por: Huynh, Hung, et al.
Publicado: (2015) -
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
por: Doleschel, Dennis, et al.
Publicado: (2021)